Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 6 September 2017, 15:35 HKT/SGT
Share:
    

Source: Eisai
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Combination Study for Lenvima (Lenvatinib) and Pembrolizumab Due to Encouraging Initial Data in Endometrial Carcinoma

TOKYO, Sept 6, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has signed an agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside of the United States and Canada) to increase the target number of endometrial carcinoma patients to be enrolled in a Phase Ib/II clinical study of its in-house discovered and developed multi-kinase inhibitor lenvatinib mesylate (product names: Lenvima/ Kisplyx, "lenvatinib") in combination with anti-PD-1 therapy pembrolizumab (brand name: KEYTRUDA), developed by Merck & Co., Inc., Kenilworth, NJ, U.S.A., due to encouraging initial data.

The decision to expand the target number of enrolled patients is based on favourable interim analysis results of the endometrial cohort in a Phase Ib/II study (Study 111) of lenvatinib in combination with pembrolizumab for multiple solid cancers, which is being jointly conducted by Eisai and Merck & Co., Inc., Kenilworth, NJ, U.S.A. The interim analysis (n = 23)(1) results indicated an objective response rate* to the combination therapy at 24 weeks of 52.2% (95% CI = 30.6 - 73.2) based on independent radiologic review and 47.8% (95% CI = 26.8 - 69.4) based on investigator review. Additionally, tumor regression was observed regardless of the state of microsatellite instability. In this study, the most frequently observed adverse events (Top 5) were hypertension, fatigue, arthralgia, diarrhea, and nausea. Based on the results of the interim analysis of Study 111, the target number of enrolled endometrial carcinoma patients will be increased to approximately 100. Patient enrollment is already underway.

Endometrial carcinoma is the sixth most common cancer in women worldwide, with 320,000 new cases diagnosed in 2012.(2) In the United States, it is estimated that there will be 60,000 new cases and 10,000 deaths by endometrial carcinoma in 2017.(3) There currently is no drug approved in 2nd line and this is where the unmet need lies.

Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai remains committed to creating new treatments for cancers with high unmet medical needs such as endometrial carcinoma, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

*Objective Response Rate: The ratio of patients whose cancer regressed at least a 30% decrease (Partial Response) or disappeared (Complete Response) after treatment.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A.

About lenvatinib mesylate (generic name, "lenvatinib", product name: Lenvima / Kisplyx)

Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the plateletderived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation. Currently, Eisai has obtained approval for lenvatinib as a treatment for refractory thyroid cancer in over 50 countries, including the United States, Japan, and in Europe, under the brand name Lenvima. Additionally, Eisai has obtained approval for the agent in combination with everolimus as a treatment for renal cell carcinoma (second-line) in over 35 countries, including the United States and in Europe. In Europe, the agent was launched under the brand name Kisplyx for renal cell carcinoma. Furthermore, in a Phase III clinical study (Study 304) comparing safety and efficacy of the agent versus the comparator sorafenib for the treatment of hepatocellular carcinoma, the agent achieved its primary endpoint of overall survival, meeting the statistical criteria for non-inferiority to sorabenib. Following the submission of applications in Japan (June 2017), the United States and Europe (July 2017), Eisai also plans to submit an application for lenvatinib for the treatment of hepatocellular carcinoma in China within the latter half of fiscal 2017.

About Phase Ib/II clinical study (Study 111) of lenvatinib in combination with pembrolizumab

Study 111 is a multicenter, open-label Phase Ib/II clinical study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab. The primary endpoint of the Phase Ib part was to determine the maximum tolerated dose. Thirteen patients with unresectable solid tumors (non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, head and neck cancer, and melanoma) who had progressed after treatment with approved therapies or for which there are no standard effective therapies available were administered 24 mg (3 patients) or 20 mg (10 patients) of lenvatinib orally daily, as well as 200 mg of pembrolizumab intravenously every three weeks. The Phase II part was conducted on patients with select solid tumors who had previously undergone less than 2 chemotherapy regimens, with a recommended dosage of 20 mg of lenvatinib daily and 200 mg of pembrolizumab every three weeks as determined based on the results of the Phase Ib part. The primary endpoint of the Phase 2 part was objective response rate, with disease control rate, clinical benefit rate, progression-free survival, and duration of response measured as secondary endpoints. Currently, the Phase II part is ongoing in the United States. In addition, Phase Ib clinical studies of lenvatinib in combination with pembrolizumab for the treatment of select solid tumors (Study 115) and hepatocellular carcinoma (Study 116) are ongoing in Japan.

About research on mechanisms of action in combination of lenvatinib and anti-PD-1 antibody(4)

In a non-clinical study where mouse models were inoculated with mouse liver cancer, melanoma or colon cancer cell lines and treated with a combination of lenvatinib with an anti-mouse PD-1 antibody, synergistic anti-tumor activity was demonstrated, based on an immunostimulatory response due to the reduction in tumor associated macrophages and the enhancement of the ratio of memory T cells by lenvatnib.

About Microsatellite Instability

When DNA replicates, there are often errors in the base sequence of DNA (mismatches). If there is a defect in the ability to repair these mismatches, the damaged DNA results in cells becoming cancerous. Microsatellites are short repeated sequences of DNA in which mismatches are very likely to occur, causing mistakes in the number of iterations. This inability to repair mismatches in the microsatellites is known as microsatellite instability (MSI). Anti-PD-1 antibodies are generally more effective in patients with a high frequency of MSI and less effective in other patients.(5)

(1) Makker V, et al. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. ASCO Meeting Abstract, 2017; #5598
(2) World Cancer Research Found International: http://www.wcrf.org/
(3) National Cancer Institute Cancer Stat Facts: https://seer.cancer.gov/statfacts/html/corp.html
(4) Kato Y, et al. Upregulation of memory T cell population and enhancement of Th1 response by lenvatinib potentiate anti-tumor activity of PD-1 signaling blockade: Lenvatineb and PD-1 mAb combination. AACR Meeting Abstract, 2017; #4614
(5) Dung T. Le. et al, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, The New England Journal of Medicine 372:2509-2520, 2015.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: